Osimertinib-induced interstitial lung disease after treatment with anti-PD1 antibody
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1573-0646
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Osimertinib-induced interstitial lung disease after treatment with anti-PD1 antibody ; day:6 ; month:9 ; year:2016 ; pages:1-3
Investigational new drugs ; (6.9.2016), 1-3
- Urheber
-
Mamesaya, Nobuaki
- Beteiligte Personen und Organisationen
-
Kenmotsu, Hirotsugu
Katsumata, Mineo
Nakajima, Takashi
Endo, Masahiro
Takahashi, Toshiaki
SpringerLink (Online service)
- DOI
-
10.1007/s10637-016-0389-9
- URN
-
urn:nbn:de:1111-2016100611354
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:53 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Mamesaya, Nobuaki
- Kenmotsu, Hirotsugu
- Katsumata, Mineo
- Nakajima, Takashi
- Endo, Masahiro
- Takahashi, Toshiaki
- SpringerLink (Online service)
Ähnliche Objekte (12)
Successful osimertinib rechallenge in a patient with advanced non-small cell lung cancer following osimertinib-induced interstitial lung disease after treatment with nivolumab
Almonertinib-induced interstitial lung disease in a lung adenocarcinoma patient complicated with interstitial lung abnormality
Drug induced interstitial lung disease
Respiratory bronchiolitis-interstitial lung disease
Interstitial lung diseases in children
Osimertinib in combination with anti-angiogenesis therapy presents a promising option for osimertinib-resistant non-small cell lung cancer
Afatinib plus osimertinib in the treatment of osimertinib-resistant non-small cell lung carcinoma: a phase I clinical trial
Clinical features and long-term outcomes of interstitial lung disease with anti-neutrophil cytoplasmic antibody
Preclinical pharmacology characterization of HX009, a novel PD1 x CD47 Bi-specific antibody
Correction: Osimertinib in combination with anti-angiogenesis therapy presents a promising option for osimertinib-resistant non-small cell lung cancer
Osimertinib as treatment for EGFR exon 20 insertion-positive lung adenocarcinoma
Clinical Atlas of Interstitial Lung Disease
Successful osimertinib rechallenge in a patient with advanced non-small cell lung cancer following osimertinib-induced interstitial lung disease after treatment with nivolumab
Almonertinib-induced interstitial lung disease in a lung adenocarcinoma patient complicated with interstitial lung abnormality
Drug induced interstitial lung disease
Respiratory bronchiolitis-interstitial lung disease
Interstitial lung diseases in children
Osimertinib in combination with anti-angiogenesis therapy presents a promising option for osimertinib-resistant non-small cell lung cancer
Afatinib plus osimertinib in the treatment of osimertinib-resistant non-small cell lung carcinoma: a phase I clinical trial
Clinical features and long-term outcomes of interstitial lung disease with anti-neutrophil cytoplasmic antibody
Preclinical pharmacology characterization of HX009, a novel PD1 x CD47 Bi-specific antibody
Correction: Osimertinib in combination with anti-angiogenesis therapy presents a promising option for osimertinib-resistant non-small cell lung cancer
Osimertinib as treatment for EGFR exon 20 insertion-positive lung adenocarcinoma
Clinical Atlas of Interstitial Lung Disease
Successful osimertinib rechallenge in a patient with advanced non-small cell lung cancer following osimertinib-induced interstitial lung disease after treatment with nivolumab
Almonertinib-induced interstitial lung disease in a lung adenocarcinoma patient complicated with interstitial lung abnormality
Drug induced interstitial lung disease
Respiratory bronchiolitis-interstitial lung disease
Interstitial lung diseases in children
Osimertinib in combination with anti-angiogenesis therapy presents a promising option for osimertinib-resistant non-small cell lung cancer
Afatinib plus osimertinib in the treatment of osimertinib-resistant non-small cell lung carcinoma: a phase I clinical trial
Clinical features and long-term outcomes of interstitial lung disease with anti-neutrophil cytoplasmic antibody
Preclinical pharmacology characterization of HX009, a novel PD1 x CD47 Bi-specific antibody
Correction: Osimertinib in combination with anti-angiogenesis therapy presents a promising option for osimertinib-resistant non-small cell lung cancer
Osimertinib as treatment for EGFR exon 20 insertion-positive lung adenocarcinoma